Literature DB >> 18334593

Doping test results dependent on genotype of uridine diphospho-glucuronosyl transferase 2B17, the major enzyme for testosterone glucuronidation.

Jenny Jakobsson Schulze1, Jonas Lundmark, Mats Garle, Ilona Skilving, Lena Ekström, Anders Rane.   

Abstract

CONTEXT: Testosterone abuse is conventionally assessed by the urinary testosterone/epitestosterone (T/E) ratio, levels above 4.0 being considered suspicious. The large variation in testosterone glucuronide (TG) excretion and its strong association with a deletion polymorphism in the uridine diphospho-glucuronosyl transferase (UGT) 2B17 gene challenge the accuracy of the T/E ratio test.
OBJECTIVE: Our objective was to investigate whether genotype-based cutoff values will improve the sensitivity and specificity of the test.
DESIGN: This was an open three-armed comparative study. PARTICIPANTS: A total of 55 healthy male volunteers with either two, one, or no allele [insertion/insertion, insertion/deletion, or deletion/deletion (del/del)] of the UGT2B17 gene was included in the study. INTERVENTION: A single im dose of 500 mg testosterone enanthate was administered. MAIN OUTCOME MEASURES: Urinary excretion of TG after dose and the T/E ratio during 15 d were calculated.
RESULTS: The degree and rate of increase in the TG excretion rate were highly dependent on the UGT2B17 genotype with a 20-fold higher average maximum increase in the insertion/insertion group compared with the del/del group. Of the del/del subjects, 40% never reached the T/E ratio of 4.0 on any of the 15 d after the dose. When differentiated cutoff levels for the del/del (1.0) and the other genotypes (6.0) were applied, the sensitivity increased substantially for the del/del group, and false positives in the other genotypes were eliminated.
CONCLUSIONS: Consideration of the genetic variation in disposition of androgens will improve the sensitivity and specificity of the testosterone doping test. This is of interest not only for combating androgen doping in sports, but also for detecting and preventing androgen abuse in society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18334593     DOI: 10.1210/jc.2008-0218

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  35 in total

Review 1.  Androgens and doping tests: genetic variation and pit-falls.

Authors:  Anders Rane; Lena Ekström
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

2.  Urinary and serum hormones profiles after testosterone enanthate administration in male hypogonadism: concerns on the detection of doping with testosterone in treated hypogonadal athletes.

Authors:  L Di Luigi; P Sgrò; F Romanelli; M Mazzarino; F Donati; M C Braganò; S Bianchini; V Fierro; M Casasco; F Botrè; A Lenzi
Journal:  J Endocrinol Invest       Date:  2009-03-24       Impact factor: 4.256

3.  Doping, sport and the community.

Authors:  Andrew Pipe; Paul C Hébert
Journal:  CMAJ       Date:  2008-08-12       Impact factor: 8.262

Review 4.  Hormones as doping in sports.

Authors:  Leonidas H Duntas; Vera Popovic
Journal:  Endocrine       Date:  2012-09-19       Impact factor: 3.633

Review 5.  Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.

Authors:  Harrison G Pope; Ruth I Wood; Alan Rogol; Fred Nyberg; Larry Bowers; Shalender Bhasin
Journal:  Endocr Rev       Date:  2013-12-17       Impact factor: 19.871

6.  UGT2B17 gene deletion associated with an increase in bone mineral density similar to the effect of hormone replacement in postmenopausal women.

Authors:  S Giroux; J Bussières; A Bureau; F Rousseau
Journal:  Osteoporos Int       Date:  2011-05-26       Impact factor: 4.507

7.  Kinetics of removal of intravenous testosterone pulses in normal men.

Authors:  Johannes D Veldhuis; Daniel M Keenan; Peter Y Liu; Paul Y Takahashi
Journal:  Eur J Endocrinol       Date:  2010-01-20       Impact factor: 6.664

8.  Potentially harmful advantage to athletes: a putative connection between UGT2B17 gene deletion polymorphism and renal disorders with prolonged use of anabolic androgenic steroids.

Authors:  Nawed Deshmukh; Andrea Petróczi; James Barker; Andrea D Székely; Iltaf Hussain; Declan P Naughton
Journal:  Subst Abuse Treat Prev Policy       Date:  2010-04-29

9.  Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease.

Authors:  Steven A McCarroll; James E Bradner; Hannu Turpeinen; Liisa Volin; Paul J Martin; Shannon D Chilewski; Joseph H Antin; Stephanie J Lee; Tapani Ruutu; Barry Storer; Edus H Warren; Bo Zhang; Lue Ping Zhao; David Ginsburg; Robert J Soiffer; Jukka Partanen; John A Hansen; Jerome Ritz; Aarno Palotie; David Altshuler
Journal:  Nat Genet       Date:  2009-12       Impact factor: 38.330

10.  Adaptive evolution of UGT2B17 copy-number variation.

Authors:  Yali Xue; Donglin Sun; Allan Daly; Fengtang Yang; Xue Zhou; Mengyao Zhao; Ni Huang; Tatiana Zerjal; Charles Lee; Nigel P Carter; Matthew E Hurles; Chris Tyler-Smith
Journal:  Am J Hum Genet       Date:  2008-08-28       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.